FIG. 3.

Epitope-specific CTL lines derived from PBMC of HIV-infected individuals (H28, H10, H19, H21, and H33) used as effectors against (i) HLA A2+ LCLs sensitized with the indicated peptide (black squares) or not sensitized (white squares) (columns headed “Peptide”), (ii) HLA A2+ LCLs infected with rVV.HIV.pt (black squares) or a control recombinant vaccinia virus (white squares) (columns headed “Polytope”), and (iii) HLA A2+ LCLs infected with rVV.nef or rVV.pol (black squares) or a control recombinant vaccinia virus (white squares) (column headed “Antigen”). The epitope listed on the left of each row was used to restimulate the bulk cultures, which were used to generate the data in that row. Bulk cultures from each individual were separately restimulated with the indicated peptide, split, and used against peptide and polytope and sometimes against whole antigen expressing target cells. A summary of patient data is shown in Table 2. The negative results, for patient H28, are shown to illustrate the specificity of the in vitro restimulation protocol.